title: Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine.
abstract: OBJECTIVE
  Weight gain is a common problem of treatment with atypical antipsychotics. However, the dimension of body weight change differs interindividually, and various genetic factors are considered to be associated with this effect. Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala polymorphism and its reported relationship to type 2 diabetes susceptibility and body mass accumulation prompted us to investigate the impact of this single nucleotide polymorphism (SNP) on antipsychotic-induced changes of body weight and body mass index (BMI) in a naturalistic study design.
  
  
  METHODS
  Included were 138 olanzapine- and 32 clozapine-treated psychiatric inpatients whose demographic data, medical anamnesis, and drug treatment were assessed at admission to hospital and 4 weeks thereafter. The PPARG Pro12Ala SNP was determined with a validated real-time PCR assay.
  
  
  RESULTS
  In contrast to previous investigations, we did not detect significant variations of weight gain among the different PPARG Pro12Ala genotypes.
  
  
  CONCLUSIONS
  Our results suggest that the examined polymorphism appears to play a minor or no role in clinical practice concerning antipsychotic drug-induced weight gain.
authors.affiliation: Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, Technische Universitt München, Munich, Germany.
authors.forename: Julia
authors.initials: J
authors.lastname: Staeker
authors.forename: Stefan
authors.initials: S
authors.lastname: Leucht
authors.forename: Werner
authors.initials: W
authors.lastname: Steimer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015992:Body Mass Index; D003024:Clozapine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D056726:Genetic Association Studies; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy / Q000235:genetics*; D008875:Middle Aged; D000077152:Olanzapine; D047495:PPAR gamma / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D015430:Weight Gain / Q000187:drug effects / Q000235:genetics*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D047495:PPAR gamma; D001569:Benzodiazepines; D003024:Clozapine; D000077152:Olanzapine